<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938261</url>
  </required_header>
  <id_info>
    <org_study_id>100-2013</org_study_id>
    <secondary_id>2013-001842-33</secondary_id>
    <nct_id>NCT01938261</nct_id>
  </id_info>
  <brief_title>The Preterm Infants' Paracetamol Study</brief_title>
  <acronym>PreParaS</acronym>
  <official_title>The Preterm Infants' Paracetamol Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <authority>Finland: Fimea (former: Valvira)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Present randomized, controlled, double-blind trial investigates the efficacy and safety of
      early (&lt;24 h) intravenous paracetamol therapy for both the early closure of the ductus and
      pain medication in very small premature infants. This phase 2 drug study focuses on the
      efficacy and safety of short-term use. The pharmacokinetics and pharmacodynamics of
      paracetamol, as well as the long-term effects, are studied.

      This study recruits preterm infants born less than 32 weeks gestational age and treated at
      the neonatal intensive care unit of Oulu University Hospital. The informed consent is asked
      from all parents. The first drug dose is given before 24 hours of age. Masked study drug is
      paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The
      loading dose is 20 mg/kg, and the maintenance dose 7.5 mg/kg every 6 hours for 4 days. The
      exact date of the closure of ductus is studied by repeated echocardiographic examinations.
      The symptoms of pain are screened by a locally used pain scale of preterm infants (NIAPAS).
      Patients are monitored for signs of possible side effects. After discharge from hospital,
      patients are examined at follow-up clinic for the first year every 3 months and at 2 years
      of age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>ductus diameter mm/kg</measure>
    <time_frame>at postnatal age of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative dosage of morphine</measure>
    <time_frame>at postnatal age of 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients who received any treatment for persistent ductus arteriosus prescribed by an attending clinician</measure>
    <time_frame>participants will be followed for the duration of NICU stay, an expected average of 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postnatal age of ductus closure</measure>
    <time_frame>participants will be followed for the duration of NICU stay, an expected average of 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left atrium to aorta ratio</measure>
    <time_frame>participants will be followed for the duration of NICU stay, an expected average of 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of apneic periods/day</measure>
    <time_frame>up to 5 days postnatal age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative NIAPAS screening score/day</measure>
    <time_frame>up to 5 days postnatal age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>participants will be followed for the duration of NICU stay, an expected average of 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>number of patients with long-term morbidity diagnoses</measure>
    <time_frame>participants will be followed until 40 weeks gestational age, an expected average of 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>number of patients who died</measure>
    <time_frame>participants will be followed until 40 weeks gestational age, an expected average of 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>number of patients with paracetamol side effects</measure>
    <time_frame>participants will be followed until 40 weeks gestational age, an expected average of 16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>paracetamol serum concentrations</measure>
    <time_frame>up to 5 days postanatal age</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Persistent Ductus Arteriosus</condition>
  <condition>Prematurity</condition>
  <condition>Pain or Discomfort in Intensive Care of Preterm Infants</condition>
  <arm_group>
    <arm_group_label>Paracetamol effect on ductus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol effect on pain</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <arm_group_label>Paracetamol effect on ductus</arm_group_label>
    <arm_group_label>Paracetamol effect on pain</arm_group_label>
    <other_name>Perfalgan 10 mg/ml infusion solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45 % saline solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Paracetamol effect on ductus</arm_group_label>
    <arm_group_label>Paracetamol effect on pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  preterm infants born &lt; 32 weeks gestational age

        Exclusion Criteria:

          -  congenital malformation

          -  lethal disease

          -  chromosomal abnormality

          -  persistent pulmonary hypertension of a newborn
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antti Harma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markku Leskinen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timo Saarela, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikko Hallman, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Outi Aikio, M.D., Ph.D.</last_name>
    <phone>+358 8 3155810</phone>
    <email>outi.aikio@ppshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pia Harkin, M.D.</last_name>
    <phone>+358 8 3155846</phone>
    <email>pia.harkin@ppshp.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Oulu Univeristy Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Outi Aikio, M.D., Ph.D.</last_name>
      <phone>+358 8 3155810</phone>
      <email>outi.aikio@ppshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Pia Harkin, M.D.</last_name>
      <phone>+358 8 3155486</phone>
      <email>pia.harkin@ppshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Outi Aikio, M.D, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pia Harkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Harma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markku Leskinen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Saarela, M.D., Ph.,D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikko Hallman, M.D.,Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 4, 2013</lastchanged_date>
  <firstreceived_date>August 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Outi Aikio</investigator_full_name>
    <investigator_title>Specialist in Pediatrics and Neonatology, M.D., Ph.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
